NCT06184204 - Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® | Biotech Hunter

Enrollment

398

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

June 22, 2025

Conditions

Atrial Fibrillation

Interventions

DRUG

Trombix® (Rivaroxaban)

20mg or 15 mg as per the doctor's prescription

Trial Locations (17)

Boumaaza Private healthcare, Algiers

CHU Mustapha, Algiers

BEDAI private healthcare, Annaba

Berboucha, Annaba

Boudjelal private healthcare, Batna City

OKBI Private healthcare, Biskra

KHAITER Private healthcare, Blida

AOUICHE private healthcare, Constantine

HAMDI private healthcare, Constantine

Mouffok private healthcare, M'Sila

Ali Lahmar private healthcare, Oran

CHU Oran, Oran

EID private healthcare, Oran

Sebbagh Private Healthcare, Sidi Bel Abbes

EPH Tipaza, Tipasa

Fernane private healthcare, Tizi Ouzou

NASSOUR private healthcare, Tlemcen